Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has shared encouraging interim results from its Phase 1b FURTHER trial, which investigates firmonertinib as a first-line monotherapy for non-small cell …
ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that it will host a virtual investor event on June 23, 2025, at 8:00 am ET. The event will focus …
ArriVent BioPharma to Host Investor Event on Groundbreaking Firmonertinib Program for EGFR Mutant NSCLC Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported its first-quarter 2025 financial results, accompanied by updates on its pipeline progress and corporate milestones. The company continues to prioritize …
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced the appointment of Merdad Parsey, M.D., Ph.D., to its Board of Directors. A respected leader in global clinical development, …
ArriVent BioPharma Appoints Dr. Merdad Parsey to Board of Directors Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (NASDAQ: AVBP) announced its 2024 financial results, showcasing significant progress in clinical programs and pipeline expansion. The company highlighted substantial milestones achieved over …
ArriVent BioPharma Reports 2024 Financial Results and Key Achievements Read More NEWTOWN SQUARE, PA and SHANGHAI, CHINA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced an exclusive license agreement with Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) for global rights outside Greater …
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside significant progress in its lead program for firmonertinib, a …
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced encouraging interim results from its global Phase 1b FURTHER trial, presented at the prestigious IASCLC 2024 World Conference on Lung …
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the second quarter of 2024, alongside significant advancements in its oncology pipeline and recent corporate …
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced that it will present significant interim findings from its randomized Phase 1b FURTHER study on firmonertinib monotherapy. This presentation …
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer Read More